Editorial · 30 Sep 2021
EditorialPublished 30 Aug 2021
Inhibition of SARS-CoV-2 Replication In vitro by Losartan
Keywords
Subjects
Pharmaceutical SciencesSimilar by topic
Short communication · 2021
Hydroxypropyl methylcellulose-based nasal sprays effectively inhibit in vitro sars-cov-2 infection and spread
Review article · 29 Jul 2020
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) Inhibition and Other Antiviral Effects of Ethiopian Medicinal Plants and Their Compounds
Editorial · 29 Jul 2021
Mutation and Replication of SARS-COV-2
Research article · 8 Jul 2024
Molecular Model of Inhibition of the Catalytic Fragment of Domain ExoN of Exoribonuclease of Virus SARS-CoV-2-Betacoronavirus B by Drug FS-1 Containing Molecular Iodine and Lithium and Magnesium Halides.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Joshua Ikoni Ogaji”

